Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) will report third quarter 2025 financial results and host a conference call on Thursday, November 13, 2025 at 8:00 a.m. Eastern Time.

The company said a press release with financial results will be issued prior to the call. Management will discuss results for the quarter ended September 30, 2025, followed by a Q&A session. Dial-in details: toll-free 1-877-451-6152, international 1-201-389-0879, Conference ID 13756828. A live webcast will be available at the provided webcast URL.

News Market Reaction

+6.47%

1 alert

+6.47% News Effect

On the day this news was published, PTHS gained 6.47%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Company to hold a conference call at 8:00 a.m. ET

DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.

Pelthos management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

Date: Time: Toll Free: International: Conf.ID:	Thursday, November 13, 2025 8:00 a.m. Eastern Time 1-877-451-6152 1-201-389-0879 13756828

Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1740524&tp_key=723fef088c

About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When will Pelthos Therapeutics (PTHS) report Q3 2025 results and hold the conference call?

Pelthos will report Q3 2025 results and hold a conference call on November 13, 2025 at 8:00 a.m. ET.

How can investors join the Pelthos (PTHS) November 13, 2025 conference call?

Dial toll-free 1-877-451-6152 or international 1-201-389-0879 and use Conference ID 13756828.

Where can I watch the Pelthos (PTHS) Q3 2025 earnings webcast?

The live webcast is available at the provided webcast URL; access the Viavid webcasts player for the November 13 presentation.

What will Pelthos management cover on the November 13, 2025 call for PTHS?

Management will discuss financial results for the quarter ended September 30, 2025 and conduct a question-and-answer period.

Will Pelthos (PTHS) release the Q3 2025 financial press release before the conference call?

Yes, the company said the financial results press release will be issued prior to the call on November 13, 2025.